Kaing A, Jaswa EA, Diamond MP, et al. - Researchers examined if and how high antimüllerian hormone (AMH) levels associate with preterm delivery risk in populations of women with polycystic ovary syndrome (PCOS) or unexplained infertility undergoing ovulation induction via performing a secondary analysis of data from two multicenter randomized clinical trials: Pregnancy in Polycystic Ovary Syndrome II (PPCOS II); and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS). They performed evaluation of live births at ≥ 24 weeks’ gestation from both the PPCOS II (n = 172) and AMIGOS (n = 222) cohorts. In the final analysis, 118 women with PCOS were included from the PPCOS II cohort and 146 women with unexplained infertility from the AMIGOS cohort. Observations revealed a high-risk for preterm delivery among women with PCOS and high AMH who conceived after ovulation induction. Data gained emphasize undertaking closer monitoring in the third trimester of pregnancies in PCOS patients with early first trimester AMH levels above 9.3 ng/mL.